---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-010495"
form_type: "8-K"
ticker: "USAQ"
cik: "0000856984"
company_name: "QHSLab, Inc."
filed_at: "2025-05-15T23:59:59+00:00"
generated_at: "2026-05-21T06:54:38.770626+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# QHSLab Q1 revenue up 32% to $645K; gross margin expands to 66.6%

## Summary
- Total revenue $645,419 vs $488,587 in Q1 2024, a 32.1% increase.
- Gross margin improved to 66.6% from 58.6% on favorable product mix.
- ISP revenue rose 28% to $162,502; Allergy Diagnostics up 11.7% to $264,913.
- New clinical study performance obligations contributed $89,100 in revenue.

## SEC filing metadata
- accession: 0001641172-25-010495
- form_type: 8-K
- ticker: USAQ
- cik: 0000856984
- company_name: QHSLab, Inc.
- filed_at: 2025-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/856984/000164117225010495/0001641172-25-010495-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/856984/000164117225010495/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-010495
- JSON: https://secwatch.observer/filing/0001641172-25-010495.json
- Plain text: https://secwatch.observer/filing/0001641172-25-010495.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.